Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive ...
How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...
COBENFY™ provides a fresh approach to schizophrenia treatment by targeting muscarinic receptors, offering patients a reduction in symptoms of psychosis with fewer metabolic side effects than ...
Please provide your email address to receive an email when new articles are posted on . “Negative symptoms” like social withdrawal as well as a history of stimulant use were predictors of a patient’s ...
On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development of Cobenfy (xanomeline-trospium), the first truly novel medication for ...
APD = Antipsychotic background drug; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; CGI-S = Clinical Global Impressions Severity Scale; mITT = modified ...
Bristol Myers Squibb and its subsidiary Karuna Therapeutics received the latest Untitled Letter from the Food and Drug Administration earlier this week. In a letter issued on December 15 to Nicole Van ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback